JP2015505959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505959A5 JP2015505959A5 JP2014545002A JP2014545002A JP2015505959A5 JP 2015505959 A5 JP2015505959 A5 JP 2015505959A5 JP 2014545002 A JP2014545002 A JP 2014545002A JP 2014545002 A JP2014545002 A JP 2014545002A JP 2015505959 A5 JP2015505959 A5 JP 2015505959A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cancer
- inhibitor
- group
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 6
- -1 p70S6K Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 3
- 102100033714 40S ribosomal protein S6 Human genes 0.000 claims 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 2
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 claims 2
- 229940125497 HER2 kinase inhibitor Drugs 0.000 claims 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims 2
- 101000656896 Homo sapiens 40S ribosomal protein S6 Proteins 0.000 claims 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 2
- 101000690268 Homo sapiens Proline-rich AKT1 substrate 1 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 2
- 239000012828 PI3K inhibitor Substances 0.000 claims 2
- 102000038030 PI3Ks Human genes 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 2
- 102100024091 Proline-rich AKT1 substrate 1 Human genes 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 2
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 229960002271 cobimetinib Drugs 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 2
- 229950008835 neratinib Drugs 0.000 claims 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 claims 1
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 claims 1
- QDITZBLZQQZVEE-YBEGLDIGSA-N (5z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=C2C=3C=CN=CC=3)C2=C1 QDITZBLZQQZVEE-YBEGLDIGSA-N 0.000 claims 1
- NERXPXBELDBEPZ-RMKNXTFCSA-N (e)-n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 NERXPXBELDBEPZ-RMKNXTFCSA-N 0.000 claims 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 claims 1
- QSUPQMGDXOHVLK-FFXKMJQXSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 QSUPQMGDXOHVLK-FFXKMJQXSA-N 0.000 claims 1
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 claims 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229940124647 MEK inhibitor Drugs 0.000 claims 1
- FOFDIMHVKGYHRU-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-4-(4-benzofuro[3,2-d]pyrimidinyl)-1-piperazinecarbothioamide Chemical compound C12=CC=CC=C2OC2=C1N=CN=C2N(CC1)CCN1C(=S)NCC1=CC=C(OCO2)C2=C1 FOFDIMHVKGYHRU-UHFFFAOYSA-N 0.000 claims 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 229950010482 alpelisib Drugs 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 229950002826 canertinib Drugs 0.000 claims 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- JXDYOSVKVSQGJM-UHFFFAOYSA-N chembl3109738 Chemical compound N1C2=CC(Br)=CC=C2CN(C)CCCCCOC2=CC3=C1N=CN=C3C=C2OC JXDYOSVKVSQGJM-UHFFFAOYSA-N 0.000 claims 1
- 229950006418 dactolisib Drugs 0.000 claims 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical group C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims 1
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 claims 1
- 229950008834 seribantumab Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161567085P | 2011-12-05 | 2011-12-05 | |
| US61/567,085 | 2011-12-05 | ||
| US201261728748P | 2012-11-20 | 2012-11-20 | |
| US61/728,748 | 2012-11-20 | ||
| PCT/US2012/068005 WO2013086031A1 (en) | 2011-12-05 | 2012-12-05 | Method of therapy selection for patients with cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017191195A Division JP2018054614A (ja) | 2011-12-05 | 2017-09-29 | 癌を有する患者に治療を選択する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505959A JP2015505959A (ja) | 2015-02-26 |
| JP2015505959A5 true JP2015505959A5 (cg-RX-API-DMAC7.html) | 2016-01-28 |
Family
ID=48574842
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014545002A Pending JP2015505959A (ja) | 2011-12-05 | 2012-12-05 | 癌を有する患者に治療を選択する方法 |
| JP2017191195A Pending JP2018054614A (ja) | 2011-12-05 | 2017-09-29 | 癌を有する患者に治療を選択する方法 |
| JP2019182229A Pending JP2020024210A (ja) | 2011-12-05 | 2019-10-02 | 癌を有する患者に治療を選択する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017191195A Pending JP2018054614A (ja) | 2011-12-05 | 2017-09-29 | 癌を有する患者に治療を選択する方法 |
| JP2019182229A Pending JP2020024210A (ja) | 2011-12-05 | 2019-10-02 | 癌を有する患者に治療を選択する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140273006A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2788752B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2015505959A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013086031A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9566334B2 (en) * | 2012-12-07 | 2017-02-14 | The General Hospital Corporation | Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
| US20140271634A1 (en) * | 2013-03-14 | 2014-09-18 | The Regents Of The University Of California | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| EP3107578A2 (en) * | 2014-02-20 | 2016-12-28 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| WO2016011558A1 (en) * | 2014-07-23 | 2016-01-28 | Ontario Institute For Cancer Research | Systems, devices and methods for constructing and using a biomarker |
| KR102439094B1 (ko) * | 2014-12-12 | 2022-08-31 | 셀퀴티 인크. | 환자를 진단 및 치료하기 위한 신호전달 경로 활성의 측정 방법 |
| CN113552350B (zh) * | 2015-04-21 | 2024-10-11 | 基因泰克公司 | 用于前列腺癌分析的组合物和方法 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| KR20180012324A (ko) * | 2015-06-29 | 2018-02-05 | 에프. 호프만-라 로슈 아게 | 타셀리십을 사용하는 치료 방법 |
| JP6745048B2 (ja) * | 2015-10-14 | 2020-08-26 | 日東紡績株式会社 | ２種のプロテインキナーゼの活性測定を用いる解析方法による、薬剤感受性ヒト細胞株の判定方法 |
| WO2017210214A1 (en) * | 2016-05-31 | 2017-12-07 | Pierian Holdings, Inc. | Methods of drug therapy selection for breast cancer patients based on her2 and her3 pathway subtyping |
| US20180117029A1 (en) * | 2016-11-03 | 2018-05-03 | Beth Israel Deaconess Medical Center, Inc. | Targeting Metabolic Vulnerability in Triple-Negative Breast Cancer |
| MX2019011769A (es) | 2017-04-03 | 2019-11-07 | Hoffmann La Roche | Anticuerpos que se unen a steap-1. |
| CN113684275B (zh) * | 2017-06-22 | 2024-02-27 | 北海康成（北京）医药科技有限公司 | 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒 |
| WO2020081956A1 (en) * | 2018-10-18 | 2020-04-23 | Medimmune, Llc | Methods for determining treatment for cancer patients |
| KR102267593B1 (ko) * | 2018-10-19 | 2021-06-21 | 주식회사 프로티나 | Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법 |
| CN111888487B (zh) * | 2020-09-04 | 2022-05-17 | 山西医科大学 | 肿瘤靶向型光声成像引导多阶段治疗纳米探针及制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
| US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
| CA2170873A1 (en) | 1993-09-03 | 1995-03-09 | Dariush Davalian | Fluorescent oxygen channeling immunoassays |
| JP2008511287A (ja) * | 2004-06-21 | 2008-04-17 | エクセリクシス， インク． | ＩＧＦＲ経路のモディファイヤーとしてのＰＦＫｓおよび使用方法 |
| RU2442171C2 (ru) | 2006-09-21 | 2012-02-10 | Промитьюс Лабораториз Инк. | Чипы на основе антител для определения множественных трансдукторов сигналов в редких циркулирующих клетках |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| AU2008276251B2 (en) | 2007-07-13 | 2014-04-24 | Nestec S.A. | Drug selection for lung cancer therapy using antibody-based arrays |
| US10416162B2 (en) * | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
| EP2602623B1 (en) * | 2008-02-25 | 2015-09-16 | Nestec S.A. | Mehtod for the detection of intracellular truncated receptors |
| US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
| EP2430443B1 (en) | 2009-05-14 | 2018-06-27 | Pierian Holdings, Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| EP2454598B1 (en) | 2009-07-15 | 2017-03-22 | DiaTech Holdings, Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
| CA2777934A1 (en) | 2009-10-20 | 2011-04-28 | Prometheus Laboratories Inc. | Proximity-mediated assays for detecting oncogenic fusion proteins |
| BR112012017084A2 (pt) * | 2010-01-12 | 2016-04-12 | Nestec Sa | métodos para previsão de resposta de câncer de mama triplo-negativo à terapia |
| US20110217701A1 (en) * | 2010-03-03 | 2011-09-08 | Carter Scott L | Prognostic Marker for Endometrial Carcinoma |
| SG10201510086VA (en) * | 2010-12-23 | 2016-01-28 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| EP2908132B8 (en) * | 2011-03-02 | 2019-06-12 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
-
2012
- 2012-12-05 JP JP2014545002A patent/JP2015505959A/ja active Pending
- 2012-12-05 WO PCT/US2012/068005 patent/WO2013086031A1/en not_active Ceased
- 2012-12-05 EP EP12855900.2A patent/EP2788752B1/en active Active
-
2014
- 2014-06-03 US US14/294,449 patent/US20140273006A1/en not_active Abandoned
-
2017
- 2017-09-29 JP JP2017191195A patent/JP2018054614A/ja active Pending
-
2019
- 2019-10-02 JP JP2019182229A patent/JP2020024210A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505959A5 (cg-RX-API-DMAC7.html) | ||
| Leto et al. | Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies | |
| Migliardi et al. | Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas | |
| Qi et al. | Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer | |
| Grünwald et al. | Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma | |
| Kudo | Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma | |
| EA201200025A1 (ru) | Биомаркеры и способы определения эффективности анти-egfr антител для лечения злокачественного новообразования | |
| RU2012134390A (ru) | Способы предсказания ответа трижды негативного рака молочной железы на терапию | |
| Ebos et al. | Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy | |
| RU2012109556A (ru) | Биологические маркеры для мониторирования ответа пациента на антагонисты vegf | |
| Bencsikova et al. | Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view | |
| Peták et al. | Integrating molecular diagnostics into anticancer drug discovery | |
| RU2013148768A (ru) | Способы предсказания и улучшения выживаемости пациентов с раком желудка | |
| Gardini et al. | Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group | |
| Milella et al. | EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy | |
| Hatch et al. | Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) | |
| Dziadziuszko et al. | Epidermal growth factor receptor (EGFR) inhibitors and derived treatments | |
| Wang et al. | EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab | |
| Baselga et al. | Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788 | |
| Sudhindra et al. | Biomarkers, prediction, and prognosis in non–small-cell lung cancer: a platform for personalized treatment | |
| Song et al. | Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib | |
| Matoori et al. | Contrast-enhanced CT density predicts response to sunitinib therapy in metastatic renal cell carcinoma patients | |
| US10640830B2 (en) | Drug selection for non-small cell lung cancer therapy | |
| JP2015527341A5 (cg-RX-API-DMAC7.html) | ||
| León et al. | Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer |